

Simultaneous Analysis of Antifungals in Plasma by SPE with Agilent Bond Elut Plexa and an Agilent 1260 Infinity LC/MS/MS

# **Application Note**

BioPharma

## Abstract

Multicompound analysis of six systemic antifungal drugs in human plasma is effectively achieved using an Agilent LC/MS/MS system composed of an Agilent Bond Elut Plexa polymeric sorbent, an Agilent Pursuit XRs<sup>Ultra 2.8</sup> Diphenyl column, and an Agilent 1260 Infinity LC Triple Quadrupole LC/MS. Agilent Bond Elut Plexa delivered extremely clean samples, which was demonstrated by detection down to pg levels. All compounds showed near 100% recovery and a single digit % RSD. Superb linearity was achieved in the calibration curves with  $R^2 \ge 0.995$  for all compounds.

## Introduction

Systemic antifungal medications are designed to treat fungal infections in the human body. Many single-compound analyses have been reported; however, multicompound analyses with low detection limits have limited availability and have not yet been established [1-4]. The Agilent high quality, mono-disperse polymeric solid phase extraction (SPE) plate, Bond Elut Plexa, delivers clean samples to achieve extremely low-picogram (pg) detection limits of multi-antifungal drugs in human plasma. This application note presents good recovery, linearity, and precision data on antifungal drugs in human plasma.



## Author

Mike Chang Agilent Technologies, Inc. Figure 1 shows examples of systemic antifungal drugs.




Figure 1. Structures of some systemic antifungal drugs.

# **Materials and Methods**

#### **SPE** reagents and solutions

SPE sorbent:		Agilent Bond Elut Plexa 96-well plate (10 mg) (p/n A4969010)				
Sample:		100 $\mu L$ human plasma spiked with antifungals*				
Ammonia:		2% aqueous ammonia add 1 mL of NH <sub>4</sub> OH to 50 mL of water				
Methanol:		reagent grade or higher, 10% MeOH add 10 mL of MeOH to 90 mL of water				
SP	E method					
1.	Pretreatment	Dilute with 300 $\mu L$ 2% aqueous ammonia				
2.	Condition	1. 500 μL MeOH 2. 500 μL H <sub>2</sub> O				
3.	Load	400 µL diluted sample from pretreatment (100 µL of actual plasma)				
4.	Wash	500 μL 10% MeOH				
5.	Elute	Twice with 250 µL MeOH				
6.	Evaporate/ reconstitute	Evaporate under gentle air stream at room temperature and reconstitute in 100 $\mu L$ 30% MeOH				
*Difenseenazele, internal standard (IS), was sniked at 50 ng /mL in all						

\*Difenoconazole, internal standard (IS), was spiked at 50 ng/mL in all samples

Calibration samples were prepared from 0.05 to 100 ng/mL in human plasma at 0.05, 0.1, 0.5, 1, 5, 10, 50, and 100 ng/mL. For itraconazole, linezolid, and betertanol, a concentration range of 0.5 to 100 ng/mL was used due to detection limits.

#### LC/MS conditions

Column:	Agilent Pursuit XRs <sup>Ultra 2.8</sup> Diphenyl, 2.0 x 50 mm (p/n A7521050X020)					
Instrument:	Agilent 1260 Infinity Triple Quadrupole LC/MS					
Mobile phase A:	0.1% formic acid in H <sub>2</sub> 0					
Mobile phase B:	MeOH					
Flow rate:	0.4 mL/min					
Injection volume:	5 μL					
Gradient:						
Time :	(min)	% B				
	0	30				
	2	85				
	4	95				
	5	95				
	5.1	30				
	7.0	30				
Temperature:	ambient, sample and column					
lon source:	ESI+ with Agilent Jet Stream Technology (JST) enhanced electrospray source					
Gas temperature:	300 °C					
Gas flow:	13 L/min					
Nebulizer:	45 psi					
Sheath gas temperature:	350 °C					
Sheath gas flow:	12 L/min					
Capillary:	4,000 V					
Samples:						

MS/MS		Collision	1
log P	transition	energy	Fragmentor
0.40	307.1 → 238.1	12	92
4.35	531.2 → 82.2	50	164
5.66	705.3 → 392.2	36	200
0.90	338.2 → 148.1	44	128
1.80	350.1 → 281.1	12	92
4.16	338.2 → 70.1	4	128
4.30	406.1 → 251.0	24	128
	0.40 4.35 5.66 0.90 1.80 4.16	log Ptransition $0.40$ $307.1 \rightarrow 238.1$ $4.35$ $531.2 \rightarrow 82.2$ $5.66$ $705.3 \rightarrow 392.2$ $0.90$ $338.2 \rightarrow 148.1$ $1.80$ $350.1 \rightarrow 281.1$ $4.16$ $338.2 \rightarrow 70.1$	log Ptransitionenergy $0.40$ $307.1 \rightarrow 238.1$ $12$ $4.35$ $531.2 \rightarrow 82.2$ $50$ $5.66$ $705.3 \rightarrow 392.2$ $36$ $0.90$ $338.2 \rightarrow 148.1$ $44$ $1.80$ $350.1 \rightarrow 281.1$ $12$ $4.16$ $338.2 \rightarrow 70.1$ $4$

# **Results and Discussion**

Figure 2 shows all compounds were baseline-separated chromatographically with good retention using the Agilent Pursuit XRs<sup>Ultra 2.8</sup> Diphenyl column. Excellent detection limits were achieved for most compounds with the Agilent 1260 Infinity Triple Quadrupole LC/MS, down to the 0.05 ng/mL level in human plasma.




Figure 2. MS chromatogram for antifungal drugs at 10 ng/mL spiked in human plasma (IS was spiked at 50 ng/mL).

All compounds showed great linearity with  $R^2 \ge 0.995$  over the entire calibration range (Figure 3).




Figure 3. Calibration curves for antifungals in human plasma from 0.05 to 100 ng/mL (itraconazole, linezolid, and bitertanol use a 0.5 to 100 ng/mL range due to LOD).

A recovery experiment was performed with n = 6 samples for four different concentration levels: 1, 5, 50, and 100 ng/mL spiked in human plasma. Most of the compounds showed excellent recovery and % RSD values for all concentration levels.

	LOD	L00	1 ng/mL		5 ng/mL		50 ng/mL		100 ng/mL		Correlation
	(ng/mL)	(ng∕mL)	Recovery (%)	RSD (%)	coefficient R <sup>2</sup>						
Fluconazole	0.05	0.05	104	1.7	97.0	3.8	100	1.4	105	2.1	0.998
Ketoconazole	0.05	0.1	101	1.6	101	2.6	104	3.4	106	4.5	0.999
ltraconazole	0.5	0.5	93.4	5.1	97.8	4.7	88.6	4.1	85.3	5.2	0.995
Linezolid	0.5	1	103	1.9	103	2.5	102	2.5	110	2.2	1.0
Voriconazole	0.05	0.1	96.8	2.1	94.4	4.4	91.9	8.2	93.4	8.8	1.0
Bitertanol	0.5	1	102	5.9	99.5	3.9	107	1.4	106	3.5	0.997

## Conclusion

A reproducible and accurate analytical method was developed for several antifungal drugs in human plasma. Agilent Bond Elut Plexa delivered clean samples, which was demonstrated by the detection of pg levels of antifungals. All compounds showed close to 100% recovery and a single digit % RSD with n = 6samples. Superb linearity was achieved in the calibration curves with  $R^2 \ge 0.995$  for all compounds.

#### References

- 1. K. Y. Beste, O. Burkhardt, and V. Kaever. (2011) "Rapid HPLC-MS/MS method for simultaneous quantitation of four routinely administered triazole antifungals in human plasma". Clinica Chimica Acta, 413, 240 - 245.
- 2. R. J. Mitchell, R. Christian, H. Hughes, A. Miah, and D. K. Walker. (2010) "The application of fully automated on-line solid phase extraction in bioanalysis". Journal of Pharmaceutical and Biomedical Analysis, 52, 86 – 92.
- 3 M-C. Verdier, D. Bentué-Ferrer, O. Tribut, and E. Bellissant. (2010) "Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma". Clinical Chemistry and Laboratory Medicine, 48 (10), 1515 - 1522.
- 4. B. V. Araujo, D. J. Conrado, E. C. Palma, and T. Dalla Costa. (2007) "Validation of rapid and simple LC-MS/MS method for determination of voriconazole in rat plasma". Journal of Pharmaceutical and Biomedical Analysis, 44, 985 – 990.

## For More Information

These data represent typical results. For more information on our products and services, visit our Web site at www.agilent.com/chem.

#### www.agilent.com/chem

Agilent shall not be liable for errors contained herein or for incidental or consequential damages in connection with the furnishing, performance, or use of this material.

Information, descriptions, and specifications in this publication are subject to change without notice.

© Agilent Technologies, Inc., 2013 Printed in the USA February 19, 2013 5990-9729EN



**Agilent Technologies**